Director

Will an Effective Drug Ever Reach the Market for Geographic Atrophy?

Roche/Genentech’s lampalizumab fails Phase III development for geographic atrophy Genentech reported on November 9, 2017 that lampalizumab failed to meet the primary end point for reducing mean change in geographic atrophy (GA) lesion area compared with sham treatment at one year in CHROMA, its second Phase III trial in GA.1 Although these results are not […]

Teva Nabs First True Generic Salmeterol/Fluticasone Propionate Launch in the United States, While GlaxoSmithKline Keeps its Cool

Teva recently launched the first true generic salmeterol/fluticasone propionate for asthma in the United States, but in a surprise twist, the generic is an authorized generic to Teva’s own “branded-generic” salmeterol/fluticasone propionate, AirDuo RespiClick, and is not directly substitutable with GlaxoSmithKline’s Advair. It was a clever move on Teva’s part to get approval for a […]